[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"schizophrenia-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:schizophrenia-disorders":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,27,0,25,[9,57,82,111,138,168,198,230,257,282,310,350,376,398,433,465,483,514,537,569,593,615,645,668,692],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100623571","medical-phenotyping-of-nhs-general-adult-psychiatry-gap-inpatients-100623571",false,"NCT07398365","Medical Phenotyping of NHS General Adult Psychiatry (GAP) Inpatients","Inclusion:\n\n\\- Adults aged between 18 and 65 years admitted to GAP wards during recruitment period\n\nExclusion:\n\n\\- Admissions to non-GAP wards (e.g., forensic psychiatry, young people's units, perinatal, old age psychiatry, or general medical wards)","ALL","18 Years","65 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","This observational study will characterise the general psychiatric and general medical phenotypes of 100 adults, sequentially admitted to NHS General Adult Psychiatry (GAP) \"mental health\" inpatient wards, providing the first detailed information on morbidity in this patient population.",[25,26,27,28],"Bipolar Affective Disorder","Schizophrenia Disorders","Depression Disorders","Personality Disorders",[30,31,32,33,34,35,36,37,38,39,40,41,42,43],"General Adult Psychiatry","mental health","physical health","inpatients","schizophrenia","NHS","Bipolar affective disorder","depression","psychosis","treatment resistance","personality disorder","cardiometabolic disease","cancer","respiratory disease","RECRUITING","2026-06-30",{"date":47,"type":48},"2026-07-01","ACTUAL",{"date":50,"type":48},"2024-04-03",{"date":52,"type":21},"2026-12-31",{"name":54,"class":55},"University of Edinburgh","OTHER",1,{"id":58,"slug":59,"hasResults":12,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":56},"100567938","phase-1-the-purpose-of-this-study-is-to-determine-the-safety-tolerability-and-pharmacokinetics-of-brexpiprazole-long-acting-injection-following-a-single-administration-in-healthy-subjectspatients-with-schizophrenia-100567938","NCT06674694","The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects\u002FPatients With Schizophrenia.","A Phase I Clinical Study of the Safety, Tolerability, and Pharmacokinetics of a Single Dose of Brexpiprazole Long-acting Injection in Healthy Subjects\u002FPatients With Schizophrenia.","Inclusion Criteria:\n\nHealthy Volunteers:\n\n1. Male and female subjects aged 18 to 65 years (including) at the time of signing the informed consent (the number of single sex in each group is not less than 1\u002F4);\n2. Body mass index (BMI) in the range of 19.0-26.0 (including the critical value), and female weight ≥ 45 kg, male weight ≥ 50 kg;\n3. Subjects of childbearing potential (including partners) have no pregnancy plan or sperm donation and egg donation plan since signing the informed consent form to within 1 year after the last dose of the investigational drug, and voluntarily take effective contraceptive measures;\n4. Sign informed consent before the trial, and fully understand the trial content, process and possible adverse reactions;\n5. Subjects can communicate well with the investigator, and understand and comply with the requirements of this study.\n\nPatients with schizophrenia:\n\n1. Male and female subjects aged 18 to 65 years (including) at the time of signing the informed consent (the number of single sex in each group is not less than 1\u002F4);\n2. Patients diagnosed with schizophrenia according to ICD-10, and the positive and negative symptom scale (PANSS) score ≤ 70 points, and the investigator judged stable disease within 4 weeks before screening;\n3. Body mass index (BMI) ≥ 18.5 kg\u002Fm2 and \\\u003C 35.0 kg\u002Fm2, and female weight ≥ 45 kg, male weight ≥ 50 kg;\n4. Subjects need to complete the tolerance test according to the protocol requirements;\n5. Subjects of childbearing potential (including partners) have no pregnancy plan or sperm donation and egg donation plan since signing the informed consent form to within 1 year after the last dose of the investigational drug, and voluntarily take effective contraceptive measures;\n6. Subjects and their guardians signed informed consent;\n7. Subjects and their guardians agree to comply with the protocol and cooperate with the investigator to complete the trial.\n\nExclusion Criteria:\n\nHealthy Volunteers:\n\n1. History of cardiovascular system (such as history of ischemic heart disease), endocrine system, urinary system, nervous system, hematology, immunology (including personal or family history of hereditary immunodeficiency), metabolic abnormalities, and the researchers believe that there is still clinical significance;\n2. Physical examination, vital signs, 12-lead electrocardiogram, clinical laboratory tests (including hematology, urinalysis, serum biochemistry, thyroid panel, coagulation panel, serum prolactin, virological examination, lipid panel, serum pregnancy test (only women of childbearing age) and glycosylated hemoglobin, etc.), chest X-ray or CT and B-ultrasound with Injection site results in injection site are abnormal and clinically significant;;\n3. Those who have taken any brexpiprazole preparation within 28 days prior to oral tolerance test drugs (brexpiprazole tablets);\n4. Those who have been enrolled in clinical trials of brepiprazole long-acting injection and have received the test drug administration;\n5. Participate in any drug or medical device clinical trial and receive the treatment of the investigational drug or medical device within 28 days before dosing (other than the drug\u002Fequipment used in this study), except for subjects participating in the research or observational study;\n6. Those who have used any drugs that interact with brepiprazole within 30 days before administration \\[including CYP3A4 inducers and inhibitors, CYP2D6 inducers and inhibitors\\] (except topical preparations with local effects);\n7. Those who have used any drugs within 14 days before administration \\[including prescription drugs, over-the-counter drugs, traditional Chinese medicine, etc.\\] (except topical preparations with local effects);\n8. Consumption of foods or beverages rich in xanthine (such as sardines, animal liver, etc.), grapefruit (such as grapefruit, western grapefruit, lime, carambola, etc.), caffeine (such as coffee, strong tea, cola, milk tea, etc.) within 48 hours before dosing, or other special diet that can affect drug absorption, distribution, metabolism and excretion;\n9. Those who drink excessive amounts (more than 8 cups, 1 cup = 250 mL) of tea or coffee or beverages rich in xanthine\u002Fcaffeine\u002Fgrapefruit (such as milk tea, cola, fruit juice, etc.) before administration;\n10. Previous alcohol abuse (i.e., men drink more than 28 standard units per week, women drink more than 21 standard units per week (1 standard unit contains 14 g alcohol, such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine), or frequent alcohol consumption within the first 6 months before screening (more than 14 standard units per week) and determined by the investigator to affect the test, or unwilling to stop drinking or any alcohol-containing products from the date of screening to the last PK blood collection period;\n11. Those who smoke more than 3 cigarettes per day within 3 months before dosing, or are unwilling to stop using any tobacco products from the date of screening to the last PK blood collection in the trial;\n12. Those with a history of drug dependence or a history of drug abuse;\n13. Positive urine drug abuse screening;\n14. Alcohol breath test positive;\n15. Those who donate blood or transfuse blood products or use blood products within 1 month before administration (\\> 200 mL);\n16. Those who have undergone surgery within 1 month before administration, or who plan to undergo surgery from the date of screening to the last PK blood collection period of the trial;\n17. Those who are allergic or allergic to any component of this product and excipients (allergic to two or more drugs or food);\n18. History of needle sickness or blood sickness with clinical significance judged by the investigator to;\n19. Pregnant or lactating women;\n20. Those who have unprotected sex within 2 weeks prior to administration;\n21. The investigator judged that it was not suitable to participate in this trial.\n\nPatients with schizophrenia:\n\n1. Patients with other psychiatric diseases other than schizophrenia diagnosed according to ICD-10 (except the diagnosis of concomitant symptoms of schizophrenia);\n2. Participate in any drug or medical device clinical trial and receive the treatment of the investigational drug or medical device within 28 days before dosing (other than the drug\u002Fequipment used in this study), except for subjects participating in the research or observational study;\n3. Those who have taken any brexpiprazole tablets for tolerance testing within 28 days prior to oral tolerance test drugs (brexpiprazole tablets);\n4. Those who have been enrolled in the clinical trial of brexpiprazole long-acting injection and received the test drug administration;\n5. More than 1 other antipsychotic drug was used before administration (except for the brexpiprazole tablets given for tolerance testing, which can be combined with ≤ 1 other antipsychotic drug and the drug has been treated at a stable dose for ≥ 14 days before administration);\n6. Those who have received other antipsychotic long-acting injection treatment and the interval from the first dose is shorter than that of the long-acting injection;\n7. Patients with clinically significant cardiovascular and cerebrovascular diseases, including but not limited to: Concomitant cardiac insufficiency, Severe arrhythmias requiring treatment, Ischemic heart disease requiring treatment, Previous or current congenital heart disease, Previous or present severe organic heart disease, History of stroke or transient ischemic attack within 1 year prior to screening, QTc interval ≥ 450 ms in men or ≥ 470 ms in women, Orthostatic hypotension (decrease in systolic blood pressure (SBP) ≥ 20 mmHg or diastolic blood pressure (DBP) ≥ 10 mmHg within 3 minutes after changing from supine to upright position), Heart rate \\\u003C 50 bpm or \\> 100 bpm at rest, Uncontrolled hypertension (SBP \\> 160 mmHg and\u002For DBP \\> 100 mmHg);\n8. Patients with poorly controlled diabetes (HbA1c ≥ 7.0%);\n9. Pre-dose hematopoiesis and major organ function indicators meet any of the following criteria: White blood cell count \\\u003C 3.0 × 109\u002FL, neutrophil count \\\u003C 1.5 × 109\u002FL, platelet count \\\u003C 75 × 109\u002FL, red blood cell count \\\u003C 3.0 × 1012\u002FL, hemoglobin \\\u003C 100 g\u002FL;Total bilirubin \\> 2 times the upper limit of normal, alanine aminotransferase \\> 2 times the upper limit of normal, and aspartate aminotransferase \\> 2 times the upper limit of normal;Creatinine \\> 1.5 times the upper limit of normal;Creatine kinase \\> 3 times the upper limit of normal;\n10. Previous alcohol abuse (i.e., men drink more than 28 standard units per week, women drink more than 21 standard units per week (1 standard unit contains 14 g alcohol, such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine), or frequent alcohol consumption within the first 6 months before screening (more than 14 standard units per week) and determined by the investigator to affect the test, or unwilling to stop drinking or any alcohol-containing products from the date of screening to the last PK blood collection period;\n11. Those who drink excessive amounts (more than 8 cups, 1 cup = 250 mL) of tea or coffee or beverages rich in xanthine\u002Fcaffeine\u002Fgrapefruit (such as milk tea, cola, fruit juice, etc.) before administration;\n12. Those who smoke more than 3 cigarettes per day within 3 months before dosing, or are unwilling to stop using any tobacco products from the date of screening to the last PK blood collection in the trial;\n13. Alcohol breath test positive;\n14. Those with a history of drug dependence or a history of drug abuse;\n15. Positive urine drug abuse screening;\n16. Those who donate blood or transfuse blood products or use blood products within 1 month before administration (\\> 200 mL);\n17. Those who have undergone surgery within 1 month before dosing, or who plan to undergo surgery from the date of screening to the last PK blood collection period of the trial;\n18. Patients with Parkinson's disease, malignant syndrome or dementia-related psychosis;\n19. Previous or current tardive dyskinesia (the 8th item score of the involuntary movement scale (AIMS) ≥ 3) or severe akathisia (BARS) overall clinical assessment score of 5 points;\n20. Patients with epilepsy or convulsive diseases (except febrile convulsions);\n21. Subjects with severe suicidal tendency: the fourth and fifth items of \"suicidal ideation\" in the Columbia Suicide Severity Rating Scale (C-SSRS) answered \"Yes\" and the most recent episode within 6 months met the criteria;Or any one of the \"suicidal behavior\" in the C-SSRS answered \"yes\" and the most recent episode within 2 years met any of the 5 items;Or, in the opinion of the investigator, the subject is at serious risk of suicide;\n22. Have a history of needle sickness or blood sickness, and judged by the investigator to have clinical significance;\n23. Those who are allergic or allergic to any component of this product and excipients (allergic to two or more drugs or food);\n24. Those who have received electroconvulsive therapy within 14 days prior to screening;\n25. Positive for HBsAg, HCV-Ab, Anti-HIV, syphilis antibody;\n26. Pregnant or lactating women;\n27. Those who have unprotected sex within 2 weeks prior to dosing;\n28. Those who have used the following drugs or food before administration: Received any prescription of traditional Chinese medicine preparations, including traditional Chinese medicine, Chinese herbal decoction pieces, Chinese patent medicine, etc., within 14 days (except topical preparations with local effects), Treatment with CYP3A4 or CYP2D6 inhibitors or inducers within 7 days or 5 drug half-lives, whichever is longer (except topical preparations with local effects), Consumption of foods or beverages rich in xanthine (e.g., sardines, animal liver, etc.), grapefruit (e.g., grapefruit, grapefruit, lime, carambola, etc.), caffeine (e.g. coffee, strong tea, cola, milk tea, etc.), or other special diet that can affect drug absorption, distribution, metabolism and excretion within 48 hours;\n29. The investigator judged that it was not suitable to participate in this trial.",true,{"count":66,"type":21},56,"INTERVENTIONAL",[69],"PHASE1","Study to evaluate the safety and tolerability of single ascending doses of brexpiprazole long-acting injection in healthy subjects\u002Fpatients with schizophrenia.",[26],"2026-06-24",{"date":74,"type":48},"2026-06-29",{"date":76,"type":48},"2024-04-10",{"date":78,"type":21},"2026-10-30",{"name":80,"class":81},"Sichuan Kelun Pharmaceutical Co.,Ltd.","INDUSTRY",{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":67,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":56},"100644601","seeg-guided-dbs-for-schizophrenia-100644601","NCT07671261","SEEG-Guided DBS for Schizophrenia","Deep Brain Stimulation for Treatment-Refractory Schizophrenia: Individualized Target Selection and Efficacy","Inclusion Criteria:\n\n* Meets the International Classification of Diseases, 10th Revision (ICD-10) diagnostic criteria for schizophrenia.\n* Male or female, aged 18 to 55 years, with stable vital signs.\n* Currently presents with prominent psychotic symptoms, assessed as moderate or severe by the Positive and Negative Syndrome Scale (PANSS) or other equivalent scales.\n* Exhibits impaired social functioning, assessed as moderate or severe impairment by the Social and Occupational Functioning Assessment Scale (SOFAS) or other equivalent scales.\n* Has a history of sequential treatment with at least two antipsychotic medications of different chemical structures known for strong efficacy against positive symptoms. Treatment must have been at an adequate dose and for an adequate duration (continuous treatment at a therapeutic dose for more than 6 weeks per medication), with good treatment adherence.\n* Has been on a stable antipsychotic medication regimen for at least one month prior to enrollment.\n* Capable and willing to provide written informed consent.\n* Demonstrates good compliance and is able to cooperate with all follow-up procedures.\n\nExclusion Criteria:\n\n* Diagnosed with any psychiatric disorder other than schizophrenia.\n* Presence of a severe personality disorder.\n* History of severe neurological diseases, such as seizures or hemorrhagic stroke.\n* Presence of structural brain abnormalities.\n* Previous history of stereotactic neurosurgery.\n* Contraindications to general anesthesia or stereotactic neurosurgery.\n* Any current or anticipated condition-including medical, psychological, social, familial support, or geographical factors-that might compromise patient safety or interfere with successful participation in the study.","55 Years",{"count":91,"type":21},46,[93],"NA","This is a prospective, randomized, interventional study designed to evaluate the efficacy and safety of SEEG-guided deep brain stimulation (DBS) for symptom improvement in patients with treatment-resistant schizophrenia. Using stereo-electroencephalography (SEEG) to record brain activity, we will identify specific abnormal electrophysiological targets and signal features associated with clinical symptoms, followed by a 12-month open-label stimulation period. The study is conducted in three stages: Stage 1 consists of SEEG brain mapping, screening of intervention targets, and optimization of stimulation parameters; Stage 2 consists of DBS implantation surgery and further optimization of stimulation parameters; Stage 3 is a randomized crossover treatment phase, followed by an open-label treatment period.",[26,96],"Schizo Affective Disorder",[98,99,100,101],"Schizophrenia","Stereoelectroencephalography","Neuroimaging","deep brain stimulation","2026-06-22",{"date":104,"type":48},"2026-06-26",{"date":106,"type":48},"2025-08-17",{"date":108,"type":21},"2028-12-31",{"name":110,"class":55},"Ruijin Hospital",{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":64,"sex":16,"minAge":17,"maxAge":89,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100643022","non-coding-rnas-gene-expression-in-psychiatric-disorders-100643022","NCT07649993","Non-Coding RNAs Gene Expression in Psychiatric Disorders","Gene Expression Analysis of Non-coding RNAs in Psychiatric Disorders","PsiRNA26","Inclusion Criteria (patients):\n\n* Age between 18 and 55 years;\n* Male sex or female sex in the mid-luteal phase of the menstrual cycle;\n* Clinical presentation consistent with diagnostic criteria for:\n* Bipolar Disorder type I or II,\n* Panic Disorder,\n* Major Depressive Disorder,\n* Obsessive-Compulsive Disorder,\n* Schizophrenia;\n* First diagnosis and drug-naive status, or absence of psychopharmacological treatment for at least 6 months prior to enrollment.\n\nInclusion Criteria (Healthy Control):\n\n* Age between 18 and 55 years;\n* Male sex or female sex in the mid-luteal phase of the menstrual cycle;\n* No treatment with psychotropic medications;\n* Absence of clinical elements supporting a diagnosis of Bipolar Disorder, Panic Disorder, Major Depressive Disorder, Obsessive-Compulsive Disorder, Schizophrenia;\n* Absence of clinical or laboratory evidence of infectious or internal medicine diseases;\n* Absence of autoimmune diseases;\n* HAM-D score \\\u003C 8;\n* MRS score \\\u003C 11;\n* Y-BOCS score \\\u003C 7;\n* BPRS score = 18;\n* No significant stressful life events during the previous 6 months.\n\nExclusion Criteria (patients):\n\n* Current immunosuppressive, antibiotic, or hormone replacement therapy;\n* Relevant medical comorbidities, including autoimmune or internal medicine disorders;\n* Active infectious diseases or infections resolved less than 3 weeks before enrollment;\n* Relevant psychiatric comorbidities;\n* Current psychopharmacological treatment or discontinuation of psychopharmacological therapy less than 6 months before enrollment.",{"count":120,"type":21},384,"This study aims to investigate whether specific non-coding RNAs, molecules involved in the regulation of gene expression, are altered in individuals with psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, panic disorder, and obsessive-compulsive disorder. Researchers will compare the expression levels of these molecules in patients who are drug-naïve or have been free from psychiatric treatment for at least six months with those observed in healthy volunteers.\n\nThe study will also evaluate whether the expression of these non-coding RNAs changes after approximately five months of standard psychiatric treatment. Blood samples collected during routine clinical care will be used to measure the expression levels of selected non-coding RNAs using reverse transcription quantitative polymerase chain reaction (RT-qPCR), a laboratory technique used to assess gene expression.\n\nThis is an observational study and does not assign specific treatments. All therapies will be prescribed according to standard clinical practice.\n\nThe main objective is to determine whether alterations in non-coding RNA expression may serve as biological markers of psychiatric disorders and whether these markers may help monitor treatment-related changes over time. The findings may contribute to a better understanding of the biological mechanisms underlying major psychiatric disorders and support the future development of more accurate diagnostic and therapeutic approaches.",[26,123,124,125,126],"Major Depression","Bipolar Affective Disorders","Obsessive Compulsive Disorder (OCD)","Anxiety Disorder (Panic Disorder or GAD)","NOT_YET_RECRUITING","2026-06-18",{"date":130,"type":48},"2026-06-23",{"date":132,"type":21},"2026-09-01",{"date":134,"type":21},"2028-09-01",{"name":136,"class":55},"Carmen Concerto",5,{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":67,"phases":149,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":165,"locationsCount":167},"100597185","cognitive-remediation-method-using-rhythmic-vocal-and-corporal-musical-learning-for-schizophrenia-100597185","NCT07055204","Cognitive Remediation Method Using Rhythmic, Vocal and Corporal Musical Learning for Schizophrenia","Multicenter Study Evaluating the Efficacy of a Cognitive Remediation Method Using Rhythmic, Vocal and Corporal Musical Learning for Schizophrenia Patients","ARCoS-2","Inclusion Criteria:\n\n* Patient with a diagnosis of schizophrenia or schizoaffective disorder (DSM-5 TR criteria)\n* Clinically stable (no full-time hospitalization related to schizophrenia for 3 months)\n* Regular psychiatric follow-up\n* Enrolled in at least 1 therapeutic or social out-of-home activity\n* No change in the antipsychotic treatment for 3 months (medication and\u002For dosage)\n* Have given free, informed and written consent to participate in the study.\n* Patient affiliated or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Patient with moderate to severe intellectual disability (clinical criteria)\n* Engaged in a Social rythmic or musical activity\n* Presenting an addictive comorbidity (excluding tobacco addiction and behavioural addictions)\n* Presenting a neurological pathology with cognitive impact\n* Involved in a neurocognitive remediation program","60 Years",{"count":148,"type":21},120,[93],"Schizophrenia, affecting 1% of the population, is a persistent disorder characterized by varied symptoms. Antipsychotic medications effectively address positive symptoms (delusions, hallucinations) and relapse but have limited impact on negative symptoms (e.g., blunted affect, anhedonia) and cognitive impairment. These dimensions significantly influence social functioning and quality of life. Combining non-pharmacological approaches like Cognitive Remediation (CR) and psychosocial rehabilitation alongside antipsychotic drugs is recommended to enhance overall functioning and quality of life. Current CR programs show moderate effectiveness due to patient commitment issues. However, completed programs demonstrate higher efficacy. Real-life applicability of these programs lacks sufficient data. We propose musical learning for cognitive remediation due to its established cognitive benefits in the general population, targeting executive functions, working memory, attention, and inhibition. These functions are specifically impaired in schizophrenia and thus are relevant for remediation. Though unexplored in schizophrenia, music learning seems promising due to its motivational and pleasurable aspects for long-term commitment and its transferability through embodied and situated dimensions. A pilot study (ARCoS-1) on CR by musical learning demonstrated feasibility and preliminary positive results on cognitive and negative symptoms. This project aims to assess this method's effectiveness on a larger scale. Our hypothesis posits that musical learning offers an efficient and well-received medium for CR in patients with schizophrenia.",[26],[153,154,155,156,157,158],"cognitive remediation","music","rythmic","vocal","corporal","musical learning","2026-05-07",{"date":161,"type":48},"2026-05-12",{"date":163,"type":21},"2026-09-04",{"date":108,"type":21},{"name":166,"class":55},"University Hospital, Toulouse",6,{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":176,"targetDuration":4,"studyType":67,"phases":177,"briefSummary":178,"conditions":179,"keywords":180,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":56},"100580304","volatility-in-paranoia-vip-trial-an-rct-of-changes-in-volatility-with-psychotherapy-100580304","NCT06835556","Volatility in Paranoia (VIP) Trial: An RCT of Changes in Volatility With Psychotherapy","Testing the Role of Belief Updating in Persecutory Delusions","VIP","Inclusion Criteria:\n\n* Men and women age 18 - 65.\n* Communicative in English.\n* Premorbid IQ \\>79 (WTAR)\n* Provide voluntary, written informed consent.\n* Stable medication regimen over at least the past two weeks, including the use of either an oral or intramuscular administration of an antipsychotic medication.\n* Diagnosis of a non-affective psychotic disorder (e.g. schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder)\n* A persecutory delusion scoring at least a 3 on the conviction scale of the Psychotic Symptoms Rating Scale (PSYRATS) that had persisted for at least two months and that was not considered the direct result of substance use.\n\nExclusion Criteria:\n\n* Serious medical or neurological illness known to interfere with cognitive functioning (uncontrolled\u002Funstable diabetes, uncontrolled hypothyroidism, Cushing's disease, Lupus, any demyelinating disease such as Multiple Sclerosis, HIV infection, CNS infection, unstable heart disease, active hepatitis, other significant endocrine condition, any cancer involving the CNS\u002Fbrain, any uncorrected vision problems, tardive dyskinesia).\n* History of severe head trauma with loss of consciousness \\>30 minutes.\n* Primary diagnosis of alcohol or substance use disorder or personality disorder",{"count":148,"type":21},[93],"The goal of this clinical trial is to learn whether learning and belief updating change in response to the treatment of persecutory delusions, in individuals with schizophrenia-spectrum disorders.\n\nThe main questions are:\n\n1. do prior expectations about environmental volatility reduce following effective psychotherapeutic treatment of delusions?\n2. does corresponding brain activity related to volatility change with effective treatment of delusions?\n\nParticipants will:\n\n1. engage in CBTp or TAU + phone check-ins for 16 weeks\n2. complete assessments at 4 timepoints over the course of 6 months\n3. complete an MRI when possible",[26],[98,181,182,183,184,185,186,187,188],"Delusion","Paranoia","Psychotherapy","Beliefs","Volatility","Cognitive Behavioral Therapy","CBTp","Psychosis","2026-05-04",{"date":191,"type":48},"2026-05-06",{"date":193,"type":48},"2025-01-15",{"date":195,"type":21},"2030-02-01",{"name":197,"class":55},"Vanderbilt University Medical Center",{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":16,"minAge":206,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":67,"phases":209,"briefSummary":210,"conditions":211,"keywords":214,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":227,"locationsCount":229},"100562864","the-key-to-integrated-trauma-treatment-in-psychosis-trial-100562864","NCT06608706","The Key to Integrated Trauma Treatment in Psychosis Trial","The Key to Integrated Trauma Treatment in Psychosis (Kit) Trial: A Pragmatic, Multicenter Effectiveness RCT of EMDR for Trauma Symptoms in Schizophrenia Spectrum Disorders","KIT","Inclusion Criteria:\n\n1. aged ≥ 16 years\n2. diagnosis of F20-29 in the ICD-10 assessed using SCID 5 CV\n3. reporting trauma \\> 1 month prior to assessment\n4. being currently distressed by the reported trauma(s), i.e., ≥ 5 (from 0 = not at all, to 10 = extremely) on item 21c on the Trauma and Life Events Checklist (TALE)\n5. able and motivated for engaging in trauma focused (TF) therapy\n6. able to understand and give informed consent; consent capacity for psychological treatment choices and consent to study procedures.\n\nExclusion Criteria:\n\n1. primary diagnosis of substance use\u002Falcohol dependence\n2. inability to understand spoken Norwegian\n3. organic psychosis or a neurological disorder\n4. acute state of psychosis defined as:\n\n   1. hospitalized in an acute ward the last 6 weeks or\n   2. major change in antipsychotic medication type or started\u002Fstopped antipsychotic medication last 6 weeks or\n   3. other mental health crises last 6 weeks\n5. current or previous (past 6 months) TF therapy","16 Years",{"count":208,"type":21},187,[93],"Schizophrenia spectrum disorders (SSDs) have a significant trauma etiology: trauma has been reported in 65 - 80% in this patient group and have a negative impact on prognosis. Trauma treatment is currently not offered in SSDs due to a lack of evidence. KIT is a pragmatic trial comparing the effectiveness of added trauma focused therapy, Eye Movement Desensitization and Reprocessing (EMDR) to standard treatment in SSDs.\n\nThe study will compare EMDR as add on to treatment as usual (TAU) to TAU in patients with schizophrenia spectrum disorders (SSDs). The overall aim is to examine the effectiveness of EMDR on trauma symptoms in SSDs.\n\nParticipants will receive max. 26 sessions of EMDR, and complete assessments before, during and after the course of therapy, in addition to a period of time (6 months) after therapy to examine long-term effects.",[212,26,213],"Psychiatric Diagnosis","Psychological Trauma, Historical",[188,215,216,217,218,219,220],"EMDR","Trauma treatment","Schizophrenia spectrum disorders","Childhood trauma","Psychological trauma","PTSD","2026-04-21",{"date":223,"type":48},"2026-04-24",{"date":225,"type":48},"2024-09-01",{"date":108,"type":21},{"name":228,"class":55},"Haukeland University Hospital",11,{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":64,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":237,"targetDuration":4,"studyType":67,"phases":239,"briefSummary":240,"conditions":241,"keywords":244,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":56},"100593759","brain-stimulation-to-the-hippocampus-in-schizophrenia-100593759","NCT07010614","Brain Stimulation to the Hippocampus in Schizophrenia","Theta Burst Modulation of Hippocampal-Cortical Rhythms in Schizophrenia","Inclusion Criteria:\n\n* Men and women, ages 18 to 65 years\n* Medically intractable epilepsy requiring phase II monitoring (intracranial EEG arms only)\n* DSM-V diagnosis of schizophrenia spectrum Axis I disorders including delusional disorder, brief psychotic disorder, schizophreniform disorder, schizophrenia, schizoaffective disorder (non-invasive TMS-EEG arms only).\n* Must have intellectual capacity to ensure adequate comprehension of the study and potential risks involved in order to provide informed consent\n* No current or history of major neurological disorders other than epilepsy.\n\nExclusion Criteria:\n\n* DSM5 diagnosis of intellectual disability\n* Significant head injury\n* Active suicidal ideation or history of suicide attempt within the past 1 year.\n* Medical illness affecting brain structure or function, or other uncontrolled or unstable medical condition.\n* Pregnancy or postpartum (\\\u003C6 weeks after delivery or miscarriage)\n* Inability to provide informed consent\n* Active substance abuse other than alcohol or cannabis within the past 1 year\n* Psychotic illness with a temporal relation to substance use or head injury\n* Those with a contraindication for MRIs or TMS (e.g. implanted metal).",{"count":238,"type":21},60,[93],"Schizophrenia - marked by delusions, hallucinations, and cognitive deficits - causes the most disability of any mental health condition, but existing treatments have significant side effect burden and are often ineffective. Disordered neural activity in the hippocampus likely contributes to schizophrenia symptoms, but to develop better therapies we need to understand whether hippocampal activity in schizophrenia can be systematically affected by non-invasive brain stimulation techniques like transcranial magnetic stimulation (TMS). This proposal will investigate the use of connectivity-guided theta burst brain stimulation to specifically target hippocampal function in schizophrenia, offering insights into fundamental hippocampal processes, schizophrenia pathophysiology, and potential avenues to use brain stimulation as a therapeutic tool in this devastating illness.",[26,242,243],"Mental Disorder","Psychotic Disorder",[34,245,246,247],"transcranial magnetic stimulation","TMS","EEG","2026-02-25",{"date":250,"type":48},"2026-02-27",{"date":252,"type":48},"2025-10-01",{"date":254,"type":21},"2027-09-30",{"name":256,"class":55},"Stanford University",{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":16,"minAge":263,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":67,"phases":267,"briefSummary":268,"conditions":269,"keywords":270,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":279,"locationsCount":281},"100565370","white-matter-plasticity-in-schizophrenia-100565370","NCT06641297","White Matter Plasticity in Schizophrenia","Inclusion Criteria:\n\n* Diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, or psychosis NOS\n* age 15-45\n* able to provide informed consent\n\nExclusion Criteria:\n\n* contraindications to MRI (metal implants, claustrophobia)\n* medical condition that limits use of hands (ie, arthritis)\n* Active or recent (within 6 months) substance use disorder other than nicotine","15 Years","45 Years",{"count":266,"type":21},36,[93],"Schizophrenia spectrum disorders are associated with impairment in the microstructure of white matter, the key brain tissue responsible for fast communication between different brain regions necessary for any complex task. This white matter impairment is linked to problems with cognition in schizophrenia, especially slower processing speed. This project aims to study the potential for correcting white matter deficits in schizophrenia by examining mechanisms underlying white matter structure changes in response to training on playing a mock musical instrument.",[26],[154,271,272],"training","plasticity","2026-02-18",{"date":275,"type":48},"2026-02-20",{"date":277,"type":48},"2025-01-02",{"date":52,"type":21},{"name":280,"class":55},"University of Maryland, Baltimore",2,{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":289,"targetDuration":4,"studyType":67,"phases":291,"briefSummary":292,"conditions":293,"keywords":294,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":309},"100589699","investigating-the-effect-of-diroximel-fumarate-on-glutathione-in-schizophrenia-100589699","NCT06957808","Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia","FORTUNE","Inclusion Criteria:\n\n* 18 -65 years, diagnosis of schizophrenia (Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)\n* Stable antipsychotic dose (no change for 1 month)\n* Currently stable with no evidence of relapse within the last 2 months prior to study enrolment\n* Minimum of 60 on the Positive and Negative Syndrome Scale (PANSS)\n* Capacity to provide informed consent\n\nExclusion Criteria:\n\n* History of significant co-morbid medical or neurological disorder including but not limited to HIV, malignancies, Systemic Lupus Erythematosus, sarcoidosis, autoimmune vasculitis, bone marrow transplantation\n* Current use of medication that is known to interact with DRF, live vaccines given within the period of DRF treatment, nephrotoxic medication (including but not limited to aminoglycosides, diuretics, non-steroidal anti-inflammatory drugs, Lithium)\n* Contraindications to DRF (pregnancy, women of childbearing potential not currently using effective contraception (combined pill (oestrogen \\& progesterone), progesterone -only with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, sexual abstinence), breast feeding, severe hepatic impairment, moderate renal impairment, severe active gastrointestinal disease, lymphocyte count - below the Lower Limit of Normal (LLN) for the local laboratory (e.g 1.30 x109\u002FL LLN for Viapath King's College London), suspected or confirmed progressive multifocal leukoencephalopathy (PML), presence of risk factors for PML (previous and\u002For current immunosuppressant or immunomodulatory treatment (including natalizumab, other fumaric esters including Dimethyl Fumarate (DMF) (topical or systemic)), serious infection, current or recent herpes virus infection)\n* Substance dependence\u002Fabuse other than to cigarettes\n* Current high suicide risk\n* Participation in a clinical study of unlicensed medicines within the previous 30 days\n* Presence\u002Fhistory of other acute or chronic illness that would make participating unsafe or unsuitable, any contraindication to MRI scanning (e.g. claustrophobia, metallic implants, pacemaker, vascular clips, metal in eyes, pregnancy)\n* Allergies to any of DRFs ingredients\n* Taking part in a research study involving an unlicensed medicine within the last 30 days",{"count":290,"type":21},30,[93],"Schizophrenia is a condition that causes symptoms like delusions, hallucinations, reduced motivation and muddled thinking. It is a common, severe and disabling psychiatric illness affecting about 1\u002F100 (1%) of people. It is ranked the third most disabling illness worldwide. Six in seven patients do not recover from the illness in 6-12 months and continue to experience psychotic symptoms. Therefore, there is a strong unmet need for new evidence-based treatments to target the neurobiology underlying schizophrenia. There is increasing evidence to indicate that glutathione (GSH), the main brain antioxidant, is abnormal in schizophrenia and may provide a new treatment target. In this study, the investigators plan to determine whether Diroximel Fumarate (DRF) (currently a treatment for a brain disorder called multiple sclerosis) can increase GSH in the brain of patients with schizophrenia using a brain scan (MRI) and explore whether changes in GSH are related to other brain measures (measured with MRI and EEG- which measures electrical activity in the brain), blood markers of GSH, and symptoms. During this study 30 people with schizophrenia will be recruited. Participants will take the drug DRF for two weeks, a computer will then decide randomly whether each person will continue to take DRF or a placebo\u002Fdummy pill for another two weeks. During this part of the study neither the patients nor the researchers will know which type of drug the patient is taking. Brain GSH and the other measures described will be assessed before and after taking the DRF and placebo\u002Fdummy pill. At the end of the study (2027), the investigators will see if taking DRF alters the brain chemical (GSH) in people with schizophrenia and whether this is linked to other measures and symptoms. It will also give researchers information about the best way to design future studies for patients with schizophrenia using this drug.",[26],[38,34,295,296,297,298,299],"inflammation","diroximel fumarate","neuroimaging","antioxidant","glutathione","2026-02-11",{"date":302,"type":48},"2026-02-13",{"date":304,"type":48},"2025-01-10",{"date":306,"type":21},"2027-01-20",{"name":308,"class":55},"King's College London",3,{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":318,"enrollmentInfo":319,"targetDuration":4,"studyType":67,"phases":321,"briefSummary":323,"conditions":324,"keywords":331,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":348,"locationsCount":281},"100588260","phase-2-effects-of-tirzepatide-on-alcohol-intake-in-patients-diagnosed-with-schizophrenia-and-alcohol-use-disorder-100588260","NCT06939088","Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder","Effect of Tirzepatide on Alcohol Intake and Reward Processing in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder","DUALPSYCHIATRY","Inclusion Criteria:\n\n* Informed Consent: The patient must provide both oral and written informed consent.\n* Diagnosis:\n\n  * Diagnosed with alcohol dependence according to the International Classification of Diseases, 10th Edition (ICD-10), and alcohol use disorder as per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).\n  * Diagnosed with schizophrenia spectrum disorder according to ICD-10 and DSM-5\n* AUDIT Score: Alcohol Use Disorder Identification Test (AUDIT) score greater than 15.\n* Body Mass Index (BMI): BMI of 23 kg\u002Fm² or higher.\n* Age Range: Between 18 and 70 years old (inclusive).\n* Heavy Alcohol Consumption: Defined as 4 or more heavy drinking days within a consecutive 21-day period during the 28 days preceding the baseline evaluation. The 21-day period will be selected based on the largest total alcohol consumption and the greatest number of heavy drinking days within the 28-day timeframe. This will be assessed using the Timeline Followback (TLFB) method. Heavy drinking days are defined as days with an alcohol intake of 4 or more units (48 g of alcohol) for women and 5 or more units (60 g of alcohol) for men.\n\nExclusion Criteria:\n\n* Intellectual Disability: individuals with a diagnosis of intellectual disability.\n* Acute Psychosis: Acute exacerbation of psychosis, as indicated by a score of 6 or 7 on the Clinical Global Impression-Severity (CGI-S) scale.\n* Coercive Measures: Current use of coercive measures, which includes individuals sentenced to treatment ('dom til behandling').\n* Suicidal Behaviour: Evidence of current severe suicidal behaviour, as assessed by the investigator during clinical evaluation.\n* History of Severe Alcohol Withdrawal: History of delirium tremens or alcohol withdrawal seizures.\n* Severe Withdrawal Symptoms: Clinical Institute Withdrawal Assessment of Alcohol Scale, revised (CIWA-Ar) score greater than 9 at baseline examination.\n* Severe Neurological Conditions: Presence of severe neurological diseases, including severe traumatic brain injury.\n* Diabetes: Type 1 or 2 diabetes\n* Pregnant or Potentially Pregnant Women: WOCBP who are pregnant, breastfeeding, intend to become pregnant within the next 6 months (including 16 weeks of treatment plus two months after discontinuation of semaglutide), or are not using a highly effective contraceptive method throughout the study period. Highly effective methods include combined hormonal contraception (oral, intravaginal, transdermal), progestogen-only hormonal contraception (oral, injectable, implantable), intrauterine device (IUD), intrauterine system (IUS), bilateral tubal occlusion, vasectomised partner, or sexual abstinence. WOCBP with a measured serum human chorionic gonadotropin (hCG) level greater than 3 U\u002FL at inclusion will also be excluded.\n* Liver Function: Impaired hepatic function, defined as liver transaminases greater than three times the upper limit of normal.\n* Renal Function: Impaired renal function, indicated by an estimated glomerular filtration rate (eGFR) below 50 mL\u002Fmin and\u002For plasma creatinine above 150 μmol\u002FL.\n* Pancreatic Function: History of acute or chronic pancreatitis or amylase levels more than twice the upper limit of normal.\n* Thyroid Conditions: Previous medullary thyroid carcinoma (MTC) or a family history of MTC and\u002For Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).\n* Cardiac Issues: Decompensated heart failure (NYHA class III or IV), unstable angina pectoris, or myocardial infarction within the past 12 months.\n* Uncontrolled Hypertension: Systolic blood pressure above 180 mmHg or diastolic blood pressure above 110 mmHg.\n* Alcohol Use Disorder Medication: Use of medications for alcohol use disorder (e.g., disulfiram, naltrexone, acamprosate, nalmefene) within the 28 days prior to inclusion as recorded in the Timeline Followback (TLFB) schedule.\n* Investigational Drugs: Receipt of any investigational drug within the past three months.\n* Weight-Lowering Medications: Use of other weight-lowering pharmacotherapy in the past three months.\n* Allergic Reactions: Hypersensitivity to the active substance or any of the excipients.\n* Language Barriers: Inability to speak and\u002For understand Danish.\n* Other Conditions: Any other condition that, in the investigator\\'s opinion, may interfere with participation in the trial.\n\nFor the subgroup of participants undergoing brain scans:\n\n* MRI Contraindications: any contraindications for MRI (e.g., magnetic implants, pacemaker, claustrophobia).\n* Benzodiazepine Use: Intermittent use of benzodiazepines within 12 days prior to the scanning session is not allowed. However, regular use of a stable dose of benzodiazepines is permitted.","70 Years",{"count":320,"type":21},108,[322],"PHASE2","Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for the treatment of type 2 diabetes and obesity, have shown promise as a novel treatment for alcohol use disorder (AUD). This study aims to investigate whether the Glucose-dependent Insulinotropic Polypeptide\u002FGLP-1RA tirzepatide will reduce alcohol consumption in patients with a dual diagnosis of AUD and schizophrenia, a population in dire need of improved treatment options. To further investigate the neurobiological underpinnings of a potential dampening effect on alcohol consumption, functional magnetic resonance imaging (fMRI) brain scans will be applied.\n\nThe key anticipated outcomes include:\n\n* decreased alcohol consumption and\n* reduced alcohol cue-induced brain activity in the GIP\u002FGLP-1-treated patient group compared with the placebo group. To the best of the investigators knowledge, this has never been examined before.",[325,326,327,328,26,329,330,98],"Alcohol Use Disorder","Alcohol Abuse\u002FDependence","Alcohol Dependence","Alcoholism","Schizophrenia and Disorders With Psychotic Features","Schizophrenia and Schizophrenia Spectrum Psychosis",[332,333,334,335,336,337,338,34,339,340,341],"GLP-1","Glucagon-like peptide 1","fMRI","GIP","Glucose-dependent Insulinotropic Polypeptide","Tirzepatide","Mounjaro(R)","alcohol","alcohol use disorder","dual diagnosis","2026-02-05",{"date":344,"type":48},"2026-02-10",{"date":346,"type":48},"2025-05-05",{"date":108,"type":21},{"name":349,"class":55},"Anders Fink-Jensen, MD, DMSci",{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":357,"targetDuration":4,"studyType":67,"phases":359,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":309},"100600490","randomized-clinical-trial-of-itest-a-blended-intervention-targeting-introspective-accuracy-100600490","NCT07098169","Randomized Clinical Trial of iTEST: A Blended Intervention Targeting Introspective Accuracy","iTEST R33","Inclusion Criteria:\n\n1. Voluntary informed consent to participate and capacity to consent as measured by the UCSD Brief Assessment of Capacity to Consent (UBACC)\n2. Age 18 to 65;\n3. DSM-5 diagnosis of schizophrenia or schizoaffective disorder based on a structured diagnostic interview and available medical record review;\n4. ≥ 6th grade reading level on the Wide Range Achievement Test-4 Reading subtest (needed to read instructions on device);\n5. Stable co-treatments (no hospitalizations or medication class changes in 2 months before enrollment). The investigators will determine symptom and medication stability by best-estimate history with information from medical records;\n6. Availability of a clinician (staff member, case manager, other mental health clinician) or close associate (family member, friend) with at least monthly contact who can be their informant\n7. Minimum level of functional impairment based on milestones, excluding participants who are full-time employed and financially responsible for their household.\n\nExclusion Criteria:\n\n1. Greater than moderate disorganization on the Positive and Negative Syndrome Scale (P2-Disorganization item \\>5)\n2. DSM-5 alcohol or substance dependence in past 3 months based on interview\n3. Level of care required interferes with outpatient therapy (e.g., hospitalized; severe medical illness); 4) Unable to adequately see or manually manipulate a smartphone.",{"count":358,"type":21},201,[93],"The purpose of this study is to evaluate the effectiveness of a psychosocial intervention called iTEST for people with psychotic disorders that targets introspective accuracy, or the ability to accurately gauge ones abilities. iTEST combines daily cognitive training on a mobile device with coaching that addresses recovery goals. In this trial, we will randomize people to one of two interventions conditions, iTEST or a control condition that receives coaching and cognitive training that does not emphasize introspective accuracy. Both interventions will take place over 12 weeks and participants will be asked to complete assessments at baseline, 6 weeks, 12 weeks, and 24 weeks. The primary outcome of the study is community functioning. Participants will be from three metropolitan areas: San Diego, Dallas, or Miami.",[26,362,243],"Schizoaffective Disorder",[364,365,98,188,366],"Digital health","Cognitive training","Functional rehabilitation","2026-01-22",{"date":369,"type":48},"2026-01-23",{"date":371,"type":48},"2025-09-01",{"date":373,"type":21},"2028-04-01",{"name":375,"class":55},"University of California, San Diego",{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":64,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":383,"targetDuration":4,"studyType":67,"phases":385,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":56},"100586173","visual-perception-in-schizophrenia-100586173","NCT06911931","Visual Perception in Schizophrenia","Visual Perception in Schizophrenia: Assessing Predictive Processing in the Earliest Stages of the Visual Cortical Hierarchy","Inclusion Criteria:\n\n* All Subjects\n* Aged 18-65\n* 20\u002F32 visual acuity or better (using in-house optical correction, if necessary)\n* An ability to speak English well enough to complete study assessments and to consent to the study\n* Subjects with Schizophrenia-Spectrum Disorder\n* Meets DSM-5 diagnostic criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder as confirmed by the Structured Interview for DSM-5 (SCID-5).\n* Subjects with Bipolar Disorder\n* Meets DSM-5 diagnostic criteria for bipolar disorder (type I, II, or unspecified) as confirmed by the Structured Interview for DSM-5 (SCID-5).\n\nExclusion Criteria:\n\n* All subjects\n* Presence of characteristics that could impair one's ability to comprehend the nature of the study, provide informed consent, or understand the assessment questions, including the following:\n\n  * Subject cannot read and understand the instructions well enough to complete the tasks or cannot provide informed consent.\n  * Intellectual impairment (WRAT-5 score \\\u003C 70) (at the discretion of experimenter);\n  * Actively intoxicated, as shown via patient self-report or staff report;\n  * Substance use disorder in the past 3 months;\n  * Subject considered high risk for suicidal acts (i.e., active suicidal ideation as determined by clinical interview OR any suicide attempt in 30 days prior to screening);\n  * Subject violence (involving severe\u002Flethal means or violence occurring in prior 6 months) or extreme agitation.\n  * Being in a current manic state\n  * Head injury with loss of consciousness greater than 10 minutes (at the discretion of the experimenter).\n  * Subject has had electroconvulsive therapy (ECT) in the past 8 weeks;\n  * Diagnosed with a neurological condition (tumor, stroke, brain injury) or neurological disorder, including seizure disorders. Diagnosed with pervasive developmental disorder (phone screen or medical records)\n  * Lazy eye or squint or other known ocular pathology\n* Healthy Control Subjects\n* Any lifetime psychotic disorder or history of psychiatric hospitalization (self disclosure);\n* Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days (self-disclosure); iii. First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.\n* Case-match Control Non-ill Subjects\n* Any lifetime psychotic disorder (as assessed by SCID\u002For SSD);\n* Recurrent depressive episodes or being in a current depressive episode (as assessed by SCID\u002For SSD)\n* Persistent threshold psychotic symptoms\n* History of psychiatric hospitalization;\n* Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days\n* First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.\n* Bipolar Subjects\n* Persistent threshold psychotic symptoms",{"count":384,"type":21},84,[93],"This study aims to identify novel markers of psychosis using electroencephalography (EEG).",[26,388,96],"Bipolar Disorder","2025-11-10",{"date":391,"type":48},"2025-11-12",{"date":393,"type":48},"2025-11-03",{"date":395,"type":21},"2027-01-31",{"name":397,"class":55},"University of Rochester",{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":406,"enrollmentInfo":407,"targetDuration":409,"studyType":22,"phases":4,"briefSummary":410,"conditions":411,"keywords":415,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":56},"100565403","creating-a-global-research-database-that-connects-genetic-information-and-long-term-health-data-to-improve-personalized-treatment-for-people-with-serious-mental-illness-100565403","NCT06641726","Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized Treatment for People With Serious Mental Illness","Developing an Internationally-diverse, Linked Genomic and Longitudinal Phenotypic Research Dataset to Accelerate Precision Psychiatry for Patients With Serious Mental Illness","GlobalMinds","Inclusion Criteria:\n\n\\- All participants must have an electronic health record in a primary or secondary care service.\n\nMental Health cohort(s) • Have received a diagnosis and\u002For treatment\u002Freferral for mental illness for MDD, BD, Schizophrenia.\n\n• Having an available electronic health record\n\n• Current age 18+ (no upper age limit)\n\n• Can speak English Dementia cohort\n\n• Participants aged 18+ (no upper age limit)\n\n• Currently alive and are, or have been, old age psychiatry patients\n\n•\n\nReceived relevant diagnosis or referral:\n\nEITHER\n\n• Clinical diagnosis of dementia, mild cognitive impairment (MCI) or subjective cognitive impairment (SCI) OR\n\n• Memory clinic referral\n\n• Must be willing and able to complete a validated cognitive assessment (MoCA or SLUMS).\n\nAll dementia patients will undergo the extended biomarker analysis.\n\nExclusion Criteria:\n\n\\- Mental Health cohort(s)\n\n• Patients without capacity to provide consent. Dementia cohort\n\n• Inability to understand spoken and\u002For written spoken English\n\n• Individuals with intellectual disability.\n\n• Patients with dementia in Creutzfeldt-Jakob disease (CJD), Huntington's, HIV dementia, alcohol-related dementia, intellectual disability, traumatic brain injury at any time.\n\n• Patients diagnosed with depression (only an exclusion criterion for MCI\u002FSCI patients), psychosis, bipolar disorder prior in the pre-index period - to be checked at screening.","110 Years",{"count":408,"type":21},50000,"14 Days","This observational study aims to provide new insights into the nature and classification of severe mental illness and dementias that in time should help improve diagnostic practise, and enable the development of new and improved treatments. The investigators will achieve aims by gathering information and biological samples from over 50,000 research participants and then linking this information with participants' electronic health records, genetic and other potential markers of mental illnesses (called biomarkers, derived from biological samples). The investigators will use this resource to analyse how potential risk factors - genetic, other biological and non-biological (related to the participants' life circumstances) - influence participants' experiences, symptoms, and outcomes (both mental and physical health). The investigators will also use advanced analysis to assess whether there may be better ways of grouping together and understanding the experiences of those with severe mental illnesses and dementias. Given the value and importance of this resource for advancing mental health research, the investigators will also make the data available to other researchers to pursue these broad research aims.",[412,26,413,414],"Bipolar Disorder (BD)","Major Depressive Diorder","Dementia",[416,417,418,419,420,421,422,423],"cross-sectional","observational","bioresource","biomarkers","whole genome sequencing","linked bioresource","dementia","neuropsychiatric","2025-09-30",{"date":426,"type":48},"2025-10-03",{"date":428,"type":48},"2025-05-16",{"date":430,"type":21},"2035-07-01",{"name":432,"class":81},"Akrivia Health",{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":439,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":441,"targetDuration":4,"studyType":67,"phases":442,"briefSummary":443,"conditions":444,"keywords":446,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":56},"100599965","cognitive-and-metacognitive-evaluation-in-vr-based-avatar-therapy-for-psychosis-100599965","NCT07091344","Cognitive and Metacognitive Evaluation in VR-Based Avatar Therapy for Psychosis","Evaluation of Cognitive, Metacognitive, Social Cognition and Trauma Related-Variables in Patients With Psychosis Receiving VR-Based Avatar Therapy","Meta-VR-AVATAR","\\*\\*Inclusion Criteria:\\*\\*\n\n* Adults aged 18 years or older.\n* Diagnosis of schizophrenia spectrum disorder according to DSM-5 criteria.\n* Experience of persistent auditory hallucinations for at least 3 months (PANSS hallucination score ≥ 3).\n* Stable medication dosage for at least 4 weeks prior to recruitment.\n* Fluent in the spoken language of the study site (Spanish).\n* Able to provide informed consent.\n* Regular psychiatric follow-up care.\n\n\\*\\*Exclusion Criteria:\\*\\*\n\n* Inability to identify a dominant voice for Avatar Therapy intervention.\n* Intellectual disability based on medical history.\n* Active substance abuse.\n* Central nervous system injury or neurological disorders affecting cognitive performance.\n* Severe visual impairment that precludes the use of VR technology.\n* Aversion to virtual reality or prior experience of simulator sickness.\n* Current suicidal ideation or risk.\n* Lack of cooperation or inability to comply with study procedures.",{"count":290,"type":21},[93],"This study aims to evaluate the relationship between cognitive, metacognitive and social cognition variables in patients with psychosis undergoing VR-based Avatar Therapy for the treatment of auditory hallucinations. In addition to the primary intervention, participants will be assessed using validated tools for emotion recognition, attributional style, theory of mind, neurocognition, and metacognition. The study also explores the potential role of trauma as a predisposing factor. Assessments will be conducted at four time points: screening (week 0), baseline (week 12), intervention period (weeks 12-24), and post-therapy follow-up (week 24). By investigating these variables, this study seeks to better understand their impact on treatment outcomes and contribute to the development of personalized therapeutic approaches.",[26,445],"Treatment Resistant Hallucinations",[447,448,449,450,38,451,452,453,454,455],"VR-based Avatar Therapy","cognition","metacognition","social cognition","schizophrenia spectrum disorders","auditory hallucinations","trauma and psychosis","emotion recognition","Personalized therapy","2025-08-22",{"date":458,"type":48},"2025-08-29",{"date":460,"type":48},"2024-03-01",{"date":462,"type":21},"2026-12-30",{"name":464,"class":55},"Fundació Sant Joan de Déu",{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":64,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":471,"targetDuration":4,"studyType":67,"phases":473,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":476,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":56},"100586157","activities-to-change-your-mood-a-test-of-the-acceptability-and-initial-efficacy-in-clinical-samples-and-healthy-controls-100586157","NCT06911723","Activities to Change Your Mood: A Test of the Acceptability and Initial Efficacy in Clinical Samples and Healthy Controls","Inclusion Criteria:\n\n* aged 18-65\n* schizophrenia group - have a psychotic disorder diagnosis\n* healthy control group - Do not have a current DSM-5 diagnosis via the SCID-5",{"count":472,"type":21},200,[93],"This is a study investigating how brief online activities can influence mood and attitudes.",[26],{"date":458,"type":48},{"date":478,"type":48},"2025-08-20",{"date":480,"type":21},"2028-12",{"name":482,"class":55},"University of Alabama at Birmingham",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":64,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":490,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":492,"conditions":493,"keywords":495,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":56},"100591287","dialog-understanding-disorganisation-a-language-focused-global-initiative-in-psychosis-100591287","NCT06978465","DIALOG: Understanding Disorganisation: A Language-focused Global Initiative in Psychosis","DIALOG","Inclusion Criteria:\n\n\\- English or French speaking participants, male or female; age 18-65 years. Patients who have been previously diagnosed by their treating physician based on the Diagnostic and Statistical Manual of Mental Disorders 5 Edition (DSM 5) criteria for schizophrenia or schizoaffective disorder. Ethnically and socioeconomically diverse individuals from urban catchments. Women are under-represented in psychosis studies but across sexes disorganisation is equally severe. We aim for \\>40% women in our samples via broader inclusion criteria not limited to schizophrenia.\n\nHealthy Controls group-matched with the patients for age (within 2 years), and sex matched to patient sample; and have no personal or first-degree family history of Severe Mental Disorders (SMD).\n\nExclusion Criteria:\n\nPregnancy; substance-induced psychosis with no SMD; neurological speech or auditory impairment, contraindication for MRI; Not able to give informed consent (if this is in doubt at the time of referral, we will formally test it). Not be able to speak French or English for clinical interactions; participants who are not proficient will be excluded.",{"count":491,"type":21},150,"Disorganized speech, language and communication, also called 'formal thought disorder,' is a key part of severe mental illnesses like psychosis and mood disorders. When someone's communication is disorganized, it makes social interactions difficult, increases stigma and affect educational and employment opportunities. However, we do not know much about why this happens. This project, called DIALOG, aims to understand the brain's role in disorganization by studying everyday language use instead of traditional clinical ratings. The study will look at how our brain creates predictions during interactions and how these processes break down in psychosis. This international project also includes experts with personal experience of mental illness. The study will look at speech, thinking patterns, symptoms, and brain waves. The goal of the study is to see if brain waves are disrupted in psychosis, especially in language-related problems. Speech tasks, like describing pictures, talking about a significant event, and telling a story are administered. These tasks will be audio-recorded for analysis. Non-invasive brain imaging technologies such as Magnetoencephalography (MEG) and Magnetic Resonance Imaging (MRI) are utilized. MRI creates images of the brain's structure, while MEG records magnetic activity from neurons, shown as brain waves. The MRI machine uses a large magnet to create images, and MEG captures small magnetic field changes from brain activity. Participants will also undergo clinical and neurocognitive assessments. The study will combine Large Language Models (LLM) applied to speech recordings with large scale participant data from neuroimaging tools (MRI\u002FMEG). The goal of DIALOG is to pioneer a computationally informed, molecular-to systems-level account of disorganisation, identifying the precise mechanisms that can be targeted with novel treatments. This project aims to gather speech and neuroimaging data from Montreal \\[100 healthy volunteers and 50 patients with psychosis\\], Groningen \\[17 synaptic density PET scans\\], Cardiff \\[600 participants\\] and Marburg \\[1600 participants\\] with schizophrenia, schizoaffective disorder or mood disorders and user acceptability data at Pavia and Melbourne.",[188,26,25,494],"Depressive Disorder",[496,497,498,499,500,501,502,503,504],"disorganization","MEG","language disorder","neural activity","MRI","formal thought disorder","large language models","natural language processing","psycholinguistics","2025-05-11",{"date":507,"type":48},"2025-05-18",{"date":509,"type":21},"2025-05-19",{"date":511,"type":21},"2030-04-30",{"name":513,"class":55},"Douglas Mental Health University Institute",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":64,"sex":16,"minAge":17,"maxAge":146,"enrollmentInfo":521,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":523,"conditions":524,"keywords":525,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":536,"locationsCount":56},"100591313","hyeeg-discourse-in-psychosis-a-neurobehavioural-study-100591313","NCT06978803","HYEEG Discourse in Psychosis: A Neurobehavioural Study","DISCOURSE-NB","Inclusion Criteria:\n\n1. English or French-speaking participants (as dyads matched for language preference).\n2. Ages 18-60 years.\n3. Patients meeting the operational criteria for schizophrenia or schizoaffective illness as previously diagnosed by their treating psychiatrist, based on the Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 criteria (Zipursky et al., 2020).\n4. Patients with less than 5 years of illness onset, based on the time of starting treatment with antipsychotic medication.\n\nExclusion Criteria:\n\n1. Participants should not have a primary diagnosis of Alcohol or Drug abuse or addiction (however, co-morbid substance abuse with a primary diagnosis of psychotic disorder is not an exclusion criterion).\n2. Participants should not have a severe medical disorder that would explain psychotic symptoms.\n3. Participants should not have a past or current history of a primary neurological disorder that can affect speech output\n4. Participants with IQ below 70 or a concurrent pervasive developmental disorder (e.g., autism) will also be excluded.",{"count":522,"type":21},110,"This multimodal study explores the mechanisms underlying social dysfunction in individuals with schizophrenia. It focuses on the relationship between disorganized communication and social interaction, aiming to identify measurable markers of disorganized communication and link them to clinical symptoms and social functioning.\n\nKey Research Questions:\n\nHow do neural and behavioural synchrony contribute to social impairments in schizophrenia?\n\nWhat roles do interbrain synchrony, motor imitation, reaction time, and verbal coherence play in disorganized communication?\n\nParticipants will:\n\n1. Engage in structured and semi-structured real-time social interactions while undergoing dual-brain electroencephalogram (EEG) hyperscanning to measure neural and behavioural activity.\n2. Perform nonverbal tasks such as motor imitation and reaction time assessments to investigate coordination and behavioural synchrony patterns.\n3. Participate in a clinical interview that evaluates verbal production, thought coherence, and speech organization.\n\nBy combining these assessments, the study aims to advance our understanding of how social and communication impairments manifest in schizophrenia. The findings will contribute to developing improved diagnostic tools and targeted interventions, ultimately supporting patients in achieving better social functioning and quality of life.",[188,26],[526,38,527,528,529,530,531,503],"hyperscanning eeg","imitation tasks","interbrain synchrony","motor imitation","motor behaviour","speech disorganization",{"date":507,"type":48},{"date":534,"type":48},"2024-01-16",{"date":52,"type":21},{"name":513,"class":55},{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":64,"sex":16,"minAge":17,"maxAge":89,"enrollmentInfo":545,"targetDuration":4,"studyType":67,"phases":546,"briefSummary":547,"conditions":548,"keywords":551,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":56},"100588054","cognitive-remediation-therapy-for-schizophrenia-effects-on-eeg-and-emotional-regulation-100588054","NCT06936397","Cognitive Remediation Therapy for Schizophrenia: Effects on EEG and Emotional Regulation","A Randomized Controlled EEG-GSR Study on the Effects of Cognitive Remediation Therapy on Neurophysiological and Emotional Regulation Markers in Schizophrenia","CRT-SCHZ","Inclusion Criteria (Schizophrenia Group):\n\n* Diagnosed with schizophrenia according to DSM-5 criteria\n* Age between 18 and 55 years\n* Clinically stable (no hospitalization or medication change within 1 month)\n* Minimum primary school education\n* Able to provide informed consent\n* Right-handed (for EEG protocol consistency)\n\nInclusion Criteria (Healthy Control Group):\n\n* No history of psychiatric or neurological disorders\n* Age- and gender-matched to schizophrenia group\n* No current medication affecting CNS\n* Able to provide informed consent\n* Right-handed\n\nExclusion Criteria (Both Groups):\n\n* Current or past substance use disorder (within the past year)\n* Comorbid neurological illness (e.g., epilepsy, traumatic brain injury)\n* Current use of benzodiazepines or medications that significantly affect cognitive function\n* Intellectual disability or MoCA score \\\u003C 20\n* Visual or hearing impairments that could interfere with task performance\n* Participation in a psychological intervention in the last 3 months",{"count":238,"type":21},[93],"This study aims to determine whether Cognitive Remediation Therapy (CRT) can improve attention, memory, and emotional regulation in people with schizophrenia. CRT is a structured program that includes exercises to strengthen cognitive skills such as problem-solving, working memory, and emotion regulation.\n\nThe study will recruit 60 participants: 30 individuals with schizophrenia and 30 healthy individuals of similar age and gender. Those with schizophrenia will be randomly assigned to either receive CRT or be placed on a waitlist without therapy. All participants will undergo non-invasive brain activity (EEG) and emotional response (GSR) recordings before and after the therapy.\n\nThe study's main question is: Does participating in a 12-week CRT program improve brain-based markers of attention and emotional regulation in people with schizophrenia?\n\nAdditional tests, such as memory and emotion recognition tasks and self-report questionnaires, will help assess changes in thinking skills and emotional well-being. The study may help better understand how CRT affects both brain function and quality of life in schizophrenia.",[26,549,550],"Cognitive Dysfunction","Emotion Regulation Disorders",[552,98,247,553,554,555,556,557,558,559],"Cognitive Remediation Therapy","GSR","Emotion Regulation","Executive Function","P300","Mismatch Negativity","Neurophysiological Biomarkers","Psychophysiology","2025-04-13",{"date":562,"type":48},"2025-04-20",{"date":564,"type":48},"2025-03-15",{"date":566,"type":21},"2025-10-15",{"name":568,"class":55},"Beykoz University",{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":576,"targetDuration":4,"studyType":67,"phases":577,"briefSummary":579,"conditions":580,"keywords":581,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":592},"100587120","phase-4-an-8-week-open-label-study-of-an-accelerated-and-slower-switching-to-xanomelinetrospium-following-atypical-antipsychotic-treatment-in-participants-with-schizophrenia-100587120","NCT06924255","An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline\u002FTrospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia","An 8-week Open-label, Multicenter Randomized Study of Accelerated and Slower Switching to Xanomeline\u002FTrospium Following Atypical Antipsychotic Treatment to Assess the Safety, Tolerability, and Efficacy in Participants With DSM-5 Schizophrenia","Inclusion Criteria:\n\n1. Participant is aged 18 to 65 years, inclusive, at Screening.\n2. Participant is capable of providing informed consent.\n\n   1. A signed informed consent form (ICF) must be provided before any study assessments are performed.\n   2. Participant must be fluent in English (oral and written) as the language of the ICF to consent. No translations will be permitted.\n3. Participant has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (American Psychiatric Association 2013) criteria and confirmed by MINI for Schizophrenia and Psychotic Disorder Studies version 7.0.2.\n4. Participant has not required psychiatric hospitalization, acute crisis intervention, or other increase in level of care due to symptom exacerbation within 12 weeks of Screening and is psychiatrically stable in the opinion of the Investigator.\n5. PANSS Total Score of ≤80 at Screening and Baseline Visits.\n\n   a. Score of ≤4 for the following core Positive Subscale items on PANSS: i. Item 2 (P2): Conceptual disorganization ii. Item 7 (P7): Hostility\n6. CGI-S score of ≤4 at Screening and Baseline Visits.\n7. Participant must be judged by the Investigator to be an appropriate candidate for transitioning from current oral AP medication due to safety or tolerability concerns and\u002For insufficient efficacy.\n8. Participant is taking an oral AP and the AP regimen has been stable for at least 6 weeks prior to Screening. Participants are permitted to remain on non-prohibited (see Section 5.2, Exclusion Criterion #14, and Section 7.8) psychotropic medications (that are not secondary AP treatments) other than the primary pre-switch AP that have been part of their ongoing treatment regimen.\n\n   1. For at least 6 weeks prior to Screening, the participant must be taking a single oral atypical AP medication at a dose and frequency consistent with the drug label. Low dose quetiapine (e.g., taken for sleep) taken in the 6 week prior to Screening is not exclusionary but must be discontinued by the Baseline Visit.\n   2. Participant must be currently treated with one of the following selected atypical oral AP at the same dosing regimen at package insert specified dose range for schizophrenia for ≥6 weeks:\n\n      * Risperidone\n      * Paliperidone\n      * Aripiprazole\n      * Ziprasidone\n      * Quetiapine\n      * Lurasidone\n      * Lumateperone\n      * Brexpiprazole\n      * Olanzapine No participants taking first-generation (typical) AP are to be included in the study.\n9. In the opinion of the Investigator, it is clinically appropriate for the participant to discontinue current AP therapy and initiate treatment with X\u002FT.\n10. Participant is willing and able, in the opinion of the Investigator, to discontinue all secondary AP medications prior to Baseline visit.\n11. BMI must be ≥18 and ≤40 kg\u002Fm2.\n12. Participant resides in a stable living situation and is anticipated to remain in a stable living situation for the duration of study enrollment, in the opinion of the investigator.\n13. Individuals of childbearing potential (IOCBP) must be willing and able to adhere to the contraception guidelines as defined in Appendix 1.\n\nExclusion Criteria:\n\n1. Any primary DSM-5 disorder other than schizophrenia within 6 months before Screening (confirmed using MINI version 7.0.2 at Screening). Exclusionary disorders include, but are not limited to, major depressive disorder, bipolar I or II disorder, schizoaffective disorder, obsessive compulsive disorder, and posttraumatic stress disorder. Symptoms of mild mood dysphoria or anxiety are allowed as long as these symptoms are not the primary focus of treatment.\n2. Participant has a history of moderate to severe alcohol use disorder or a substance (other than nicotine or caffeine) use disorder within the past 6 months or a positive urine drug screen (UDS) for a substance other than cannabis at Screening or Baseline.\n\n   1. Participants with mild substance use disorder within the 6 months before Screening must be discussed and agreed upon with the Principal Investigator (PI) before they can be allowed into the study.\n   2. Participants with positive UDS for cannabis are permitted to enroll in the study provided that the participants' pattern of use is not indicative of a substance use disorder.\n   3. Urine toxicology screen positive for phencyclidine, amphetamines, opiates, cocaine, or alcohol (clinically significant alcohol use in the opinion of the Investigator).\n3. History or presence of clinically significant cardiovascular (e.g., untreated or unstable hypertension, clinically significant tachycardia), pulmonary, renal, hematologic, gastrointestinal (GI, e.g., obstructive disorders \\[including conditions that may decrease GI motility, such as ulcerative colitis, intestinal atony, and myasthenia gravis\\], endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the participant or the validity of the study results.\n4. Participant with cirrhosis, biliary duct abnormalities, and\u002For hepatobiliary carcinoma based on either medical history or liver function test results.\n5. All grades of hepatic impairment (mild \\[Child-Pugh Class A\\], moderate \\[Child-Pugh Class B\\], and severe \\[Child-Pugh Class C\\]).\n6. History or high risk of urinary retention or gastric retention.\n7. History of narrow-angle glaucoma.\n8. History of irritable bowel syndrome (with or without constipation) or serious constipation requiring treatment within the last 6 months.\n9. Risk for suicidal behavior during the study as determined by the Investigator's clinical assessment. Non-suicidal self-injurious behavior is not exclusionary.\n10. Clinically significant abnormal finding on the physical examination, medical history, or clinical laboratory results at Screening.\n11. An eGFR of \\\u003C 60 mL\u002Fmin\n12. Elevations in hepatic transaminases at screening ≥3× ULN for ALT and AST and\u002For bilirubin \\> 2× ULN, unless in the context of Gilbert's syndrome\n13. History of unstable hypertension or tachycardia as evidenced by:\n\n    1. Blood pressure of ≥160\u002F100 mmHg (single seated measure) at screening\n    2. Heart rate of ≥110 bpm (single seated measure) at Screening\n14. Participant is receiving other psychotropic medications for psychiatric and neurological conditions with Anticholinergic Risk Scale (ARS) scores \\>1 (tricyclic antidepressants, paroxetine, antispasmodics, antihistamines with anticholinergic properties).\n15. History of treatment resistance to schizophrenia medications defined as:\n\n    1. Failure to respond to 2 adequate courses of pharmacotherapy (a minimum of 4 weeks at an adequate dose per the label) within the past 12 months OR\n    2. Has a history of having received clozapine\n16. Participant is receiving a long-acting injectable AP.\n17. Developmental disorder, intellectual disability, or autism spectrum disorder (by history), with the exception of participants diagnosed with autism at age \\\u003C18 due to historic diagnostic criteria precluding schizophrenia diagnoses of minors (at discretion of Investigator).\n18. Lifetime history of clinically significant head trauma.\n19. Pregnant, breastfeeding, or less than 3 months postpartum.\n20. Active biliary disease (e.g., symptomatic gallstones). Participants with other biliary histories are eligible and should be discussed with the Medical Monitor.\n21. Participants with any of the following:\n\n    1. History of bladder stones\n    2. History of recurrent urinary tract infections\n    3. For male participants, serum prostate-specific antigen \\>10 ng\u002FmL at Screening\n    4. For male participants ≥45 years of age, International Prostate Symptom Score (IPSS) of 5 (i.e., \"almost always\") on items 1, 3, 5, or 6\n    5. For male participants ≥45 years of age, an IPSS ≥9 for the sum of items 1, 3, 5, and 6\n22. In the opinion of the Investigator (and\u002For Sponsor), participant is unsuitable for enrollment in the study, or participant has any finding that, in the opinion of the Investigator (and\u002For Sponsor), may compromise the safety of the participant or affect their ability to adhere to the protocol visit schedule or fulfill visit requirements.\n23. Participant has had psychiatric hospitalization(s) for more than 30 days (cumulative) within the 12 months before Screening.\n24. Participant with prior exposure to X\u002FT or who has a history of prior X\u002FT intolerability (allergy\u002Fhypersensitivity).\n25. Risk of violent or destructive behavior in the opinion of the Investigator.\n26. Current involuntary hospitalization or incarceration.\n27. Participation in another clinical study in which the participant received an experimental or investigational drug agent within 3 months prior to Screening.",{"count":20,"type":21},[578],"PHASE4","The study design is a de-escalation of current atypical AP treatment to X\u002FT at a maintenance dose of X\u002FT established either at 100 mg xanomeline\u002F20 mg trospium chloride BID (total daily dose 200 mg xanomeline\u002F40 mg trospium chloride) or 125 mg xanomeline\u002F30 mg trospium chloride BID (total daily dose 250 mg xanomeline\u002F60 mg trospium chloride) based on participants' clinical response and\u002For tolerability. While the package insert for X\u002FT provides guidance for clinicians on dosing, this study is designed to assess how transitioning will occur in the \"real world\" situation.",[26],[98],"2025-04-10",{"date":584,"type":48},"2025-04-11",{"date":586,"type":21},"2025-04",{"date":588,"type":21},"2025-12",{"name":590,"class":591},"Collaborative Neuroscience Research, LLC","NETWORK",7,{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":603,"conditions":604,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":56},"100569306","asylumseekers-experiencing-paranoid-delusions-a-virtual-reality-study-100569306","NCT06692530","Asylumseekers Experiencing Paranoid Delusions: A Virtual Reality Study","Paranoid Behaviour & Threat Evaluation in Asylumseekers Diagnosed With a Psychotic Disorder and Experiencing Paranoid Delusions: A Phenomenological Qualitative Virtual Reality Study","COA-VR","Inclusion Criteria:\n\n* Aged 18 or over\n* Receiving treatment from CTP Veldzicht\n* Seeking asylum in the Netherlands, registered with Centraal Opvang Asielzoekers (COA)\n* Classification (primary or subsidiary classification) of a disorder categorized within the 'schizophreniaspectrum- and other psychotic disorders' (DSM-V)\n* Diagnosed with the symptom of paranoid delusion, defined as a PANSS score on the delusion item (P6) \\>2\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Acutely psychotic, which means overwhelmed by psychotic symptoms, agitated, not able to participate in an interview, as judged by a therapist or socio-therapist.",{"count":602,"type":21},15,"Rationale: Ethnic minorities and asylumseekers have a two- to three-times increased risk of psychosis compared to people from their host country. Among patients experiencing psychosis, paranoid delusions are a common symptom. Diagnostic assessments are challenging in this group because of language differences and sociocultural differences in interpersonal social behavior and communication. To fill this gap this research will make use of Virtual Reality (VR) to assess thoughts, behaviours and emotions in real-time. VR has a high ecological validity and its partial non-verbal nature has a clear potential in terms of a transcultural application among asylumseekers.\n\nObjective: The main objective of this study is to discover how asylumseekers with a psychotic disorder who are experiencing paranoid delusions behave and evaluate threat in a virtual environment.\n\nSecondary objectives: To assess the suitability and applicability of using VR within the specific population of asylumseekers with a psychotic disorder and paranoid delusions.\n\nStudy design: The study uses a mixed-methods design, combining qualitative phenomenological data and descriptive quantitative data.\n\nStudy population: Adult psychiatric patients that are seeking asylum in the Netherlands with a DSM-5 classification of a psychotic disorder and paranoid delusion (as measured by the PANSS) will be included. Furthermore, patients must receive mental health care from CTP Veldzicht, either in one of the wards (closed or open) or through ambulatory care.\n\nIntervention: The patients will be immersed in a VR-environment using a head mounted display. Four different VR-scenarios are used, each taking up three to four minutes. Using simple movement instructions, patients are asked to walk around and observe their environment.\n\nMain study parameters\u002Fendpoints: Phenomenological semi-structured interview. The interview measures the experience of participants in a qualitative matter. Audio recordings of the semi-structured interviews will be transcribed. These transcriptions containing rich qualitative data are the main study parameter. Additional descriptive qualitative data (demographic \\& symptom specific) will be gathered through questionnaires to provide quantitative insight in the sample-population (questionnaires used: PANSS, SSPS, SBQ, and VAS). Subsequently, psychiatrists working in the field of transcultural psychiatry will be interviewed about the paranoid behaviour of participants based on video and audio recordings of the VR-session.\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: Some participants might experience simulator sickness symptoms. No major adverse events are expected or have been documented in previous VR studies of our research group using the same VR hardware and software. The assessment will take approximately 90 minutes in total. No benefits are expected. An empathic and transparent approach, a clear consent procedure, close monitoring of participants' moods and consistently adverting an opt-out will be used.",[26,605],"Paranoid Delusions","2025-03-28",{"date":608,"type":48},"2025-04-02",{"date":610,"type":48},"2024-11-22",{"date":612,"type":21},"2025-07-01",{"name":614,"class":55},"University Medical Center Groningen",{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":623,"targetDuration":4,"studyType":67,"phases":625,"briefSummary":626,"conditions":627,"keywords":629,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":56},"100585826","40-hz-visual-stimulation-as-an-intervention-in-schizophrenia-100585826","NCT06907420","40 Hz Visual Stimulation as an Intervention in Schizophrenia","Effects of Multi-Session 40 Hz Visual Stimulation on Neuronal and Psychiatric Outcomes in Schizophrenia","GammaSZ","Inclusion Criteria:\n\n* Medical diagnosis of schizophrenia (F20) or schizoaffective disorder (F25)\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Any history of seizures\n* Acute suicidality assessed with the Columbia-Suicide Severity Rating Scale (C-SSRS; Brent et al., 2008)\n* Any other relevant axis 1 disorder\n* Red-green colour blindness or current ocular disease\n* Alcohol, cannabis, or illicit drug addiction within the last 3 months",{"count":624,"type":21},20,[93],"In schizophrenia, an abnormal reduction in neuronal gamma oscillations (30-100 Hz) is associated with negative symptoms such as cognitive dysfunction. The literature suggests that rescuing gamma oscillations through non-invasive brain stimulation may be an accessible and safe add-on strategy to mitigate negative symptoms. Here, a stimulation protocol based on gamma visual stimulation will be tested. This pilot study will follow an uncontrolled clinical trial design: A minimum of ten patients diagnosed with schizophrenia or a schizoaffective disorder and predominant negative symptoms will be recruited at Klinikum rechts der Isar. They will undergo a multisession stimulation protocol, consisting of one hour of 40 Hz visual stimulation per day over five consecutive days, during which they will be encouraged to fall asleep. An equal number of patients will be recruited for a treatment-as-usual group without intervention. Pre- and post-assessments will include EEG, a cognitive test battery (THINC-IT), a mood scale (PANAS), and a schizophrenia symptom scale (PANSS). This study's results will inform on the feasibility of gamma visual stimulation as a potential add-on intervention in schizophrenia.",[628,26,362],"Negative Symptoms in Schizophrenia",[630,631,34,632,247,633,634,635,636],"gamma","40 Hz","visual stimulation","neuromodulation","flicker","sleep","negative symptoms","2025-03-26",{"date":608,"type":48},{"date":640,"type":48},"2025-03-14",{"date":642,"type":21},"2025-07",{"name":644,"class":55},"Technical University of Munich",{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":649,"acronym":4,"eligibilityCriteria":650,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":651,"targetDuration":4,"studyType":67,"phases":653,"briefSummary":654,"conditions":655,"keywords":656,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":660,"lastUpdatePostDateStruct":661,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":666,"locationsCount":56},"100583915","the-effect-of-mindfulness-based-psychoeducation-programme-given-individually-to-schizophrenia-patients-on-internalised-stigma-and-healthy-lifestyle-behaviours-100583915","NCT06882538","The Effect of Mindfulness-Based Psychoeducation Programme Given Individually to Schizophrenia Patients on Internalised Stigma and Healthy Lifestyle Behaviours","Inclusion Criteria:\n\n1. Having been diagnosed with schizophrenia\n2. TRSM registered and continuing\n3. Acceptance to work and training\n\nExclusion Criteria:\n\n1. Have not been diagnosed with schizophrenia\n2. If he\u002Fshe does not agree to participate in the study\n3. If not registered with TRSM",{"count":652,"type":21},40,[93],"Schizophrenia is a chronic, recurrent and disabling illness that usually lasts a lifetime and causes serious problems in quality of life and functioning. Psychoeducation programmes added to drug treatment in the treatment of schizophrenia have been shown to increase the knowledge of patients and their relatives about the disease, coping skills, prevention of exacerbations and relapses of the disease, social functioning, insight into the disease, compliance with drug treatment and quality of life. Rehabilitated individuals diagnosed with schizophrenia who are registered and continuing at Kastamonu Training and Research Community Mental Health Centre will constitute the population, and individuals who continue between April 2024 and May 2024 will constitute the sample. The research will be conducted with schizophrenic patients in a pre-test-post-test, experimental and control group experimental design. Power analysis will be performed to determine the number of people to be sampled and calculated with the G\\*Power 3.1 programme. 40 people will be reached in the groups, 20 people in the experimental group and 20 people in the control group. In the evaluation of the data, descriptive statistical methods (Mean, Standard deviation) as well as the correlation test will be used to evaluate the relationship between the average scores before and after the training in the comparison of quantitative data. Wilcoxon related sample test will be used to make comparisons before and after the training. Personal Information Form, Internalised Stigma Scale in Mental Illness (ISIS) and Healthy Lifestyle Behaviours (HBSB) scale will be used to collect the data. Awareness-based psychoeducation programme will be applied to the experimental group. The aim of psychoeducation is to create a change in knowledge and behaviour towards healthy lifestyle behaviours (1- Self-actualisation, 2- Health responsibility, 3- Exercise, 4- Nutrition, 5- Interpersonal support, 6- Stress management) by reducing internalised stigma. Therefore, it will be evaluated whether the applied psychoeducation programme creates the intended change in knowledge and behaviour. This study will be conducted to examine the effect of a 6-week 12-session self-awareness-based psychoeducation programme given to schizophrenia patients on internalised stigma and healthy lifestyle behaviours. In this study, schizophrenic patients will be provided with regular psychoeducation to provide individual support, to ensure the development of coping skills for self-protection, and to gain knowledge and skills to gain a healthy lifestyle. After the prepared psychoeducation, a training guide will be created for the participants and will be given after the training, thus ensuring continuity of education.",[26],[34,657,658,659],"psychoeducation","internalised stigmatisation","healthy lifestyle behaviour","2025-03-16",{"date":662,"type":48},"2025-03-18",{"date":664,"type":48},"2025-02-14",{"date":564,"type":21},{"name":667,"class":55},"Kastamonu University",{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":672,"acronym":4,"eligibilityCriteria":673,"healthyVolunteers":64,"sex":16,"minAge":17,"maxAge":674,"enrollmentInfo":675,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":677,"conditions":678,"keywords":679,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":684,"startDateStruct":686,"completionDateStruct":688,"leadSponsor":690,"locationsCount":56},"100584254","an-integrated-neurophysiological-approach-toward-the-early-detection-of-psychiatric-disorders-100584254","NCT06886945","An Integrated Neurophysiological Approach Toward the Early Detection of Psychiatric Disorders","Inclusion Criteria (all participants):\n\n* Normal hearing\n* Normal or corrected-to-normal vision\n\nInclusion Criteria (patients):\n\n* Clinical diagnosis of schizophrenia spectrum disorder (according to DSM-5)\n* IQ \\> 70\n\nExclusion Criteria (all participants):\n\n* Anamnesis or evidence of any central nervous system alteration\n\nExclusion Criteria (patients)\n\n* Current major physical illness\n* Drug dependency\u002Fabuse over the last 6 months\n* Unstable pharmacological therapy\n* Comorbidities with other major psychiatric disorders","50 Years",{"count":676,"type":21},75,"Schizophrenia (SCZ) is a severe neuropsychiatric disorder characterized by cognitive decline, social withdrawal, and positive symptoms such as hallucinations and delusions. Research suggests that SCZ and schizotypy exist along a continuum, with shared structural and behavioral abnormalities, the latter of which encompass the sensory and perceptual domain, often in the form of altered multisensory integration, as seen in tasks like the Sound-Induced Flash Illusion (SIFI). Individuals with schizotypal traits or SCZ show enlarged temporal binding windows (TBW) of cross-modal integration, affecting perceptual accuracy and multisensory judgments. However, whether these deficits stem from overactive top-down modulation or weakened bottom-up sensory precision remains unclear.\n\nThe current study seeks to address these questions, by asking participants (healthy individuals screened as for their schizotypal traits, and patients suffering from SCZ) to complete a modified version of the SIFI, as well as an audiovisual temporal order judgment (TOJ) task. Cross-modal performance will be assessed via signal detection theory (SDT) metrics and psychometric modeling to estimate individual TBWs, thereby assaying audiovisual processing abilities along the schizotypal continuum",[26],[98,680,681,682,683],"Audio-Visual Integration","Temporal Binding Windows","Signal Detection Theory","Schizotypal Personality",{"date":685,"type":48},"2025-03-20",{"date":687,"type":48},"2024-04-09",{"date":689,"type":21},"2025-10",{"name":691,"class":55},"IRCCS Centro San Giovanni di Dio Fatebenefratelli",{"id":693,"slug":694,"hasResults":12,"nctId":695,"briefTitle":696,"officialTitle":696,"acronym":4,"eligibilityCriteria":697,"healthyVolunteers":12,"sex":16,"minAge":698,"maxAge":17,"enrollmentInfo":699,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":701,"conditions":702,"keywords":704,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":706,"lastUpdatePostDateStruct":707,"startDateStruct":709,"completionDateStruct":711,"leadSponsor":713,"locationsCount":4},"100583265","psychiatric-disorders-in-child-and-adolescent-offspring-of-parents-with-schizophrenia-and-bipolar-disorders-100583265","NCT06874075","Psychiatric Disorders in Child and Adolescent Offspring of Parents with Schizophrenia and Bipolar Disorders.","Inclusion Criteria:\n\n\\- 6\\_18 years IQ \\> 70 parents of schizophrenia \\& mood disorders .\n\nExclusion Criteria:\n\n* age \\\u003C6 or \\>18 IQ \\\u003C 70 .","6 Years",{"count":700,"type":21},50,"Offspring of parents with bipolar disorder (BD) and schizophrenia (SZ) are vulnerable and at high risk for these disorders. Despite the fact that positive family history of SZ or BD is the strongest predictor for the development of these severe mental illnesses, there is limited evidence assessing young adults of SZ and BP simultaneously with lack of detailed handling of similarities in risk and developmental trajectories during adolescence",[703,26],"Mood Disorders",[705,34],"bipolar","2025-03-11",{"date":708,"type":48},"2025-03-13",{"date":710,"type":21},"2025-05-20",{"date":712,"type":21},"2027-08-20",{"name":714,"class":55},"Assiut University"]